Applied Therapeutics pulls plans to file accelerated approval after FDA 'change in direction' — shares plummet

When the FDA lifted a clinical hold on Applied Therapeutics’ lead program in galactosemia last February, the New York biotech signaled that they were then on a smooth road toward an accelerated approval, with plans to file an NDA in the third quarter of 2021.